
Celcuity (CELC) Stock Forecast & Price Target
Celcuity (CELC) Analyst Ratings
Bulls say
Celcuity Inc. is advancing its clinical-stage therapeutic candidate, gedatolisib, a unique pan-PI3K and mTOR inhibitor, which has shown the potential for enhanced efficacy in patients with HR+/HER2- advanced breast cancer resistant to standard endocrine therapies. The company's ongoing Phase 3 trial, VIKTORIA-1, presents a promising opportunity for gedatolisib to achieve at least a three-month progression-free survival (PFS) improvement over existing treatments, thereby potentially obtaining a label for the wild-type population and enhancing market positioning. Historical data indicates that gedatolisib may outperform isoform-specific therapies in PIK3CA wild-type patients, contributing to a positive outlook for Celcuity's future performance in the biotechnology sector.
Bears say
Celcuity Inc reported no revenue for the period, alongside a net loss of $0.70 per diluted share, which was worse than the consensus estimate of a net loss of $0.65 per diluted share. The efficacy concerns regarding its lead therapeutic candidate, gedatolisib, are exacerbated by the high prevalence of ESR1 mutations in patients receiving fulvestrant, alongside significantly unfavorable progression-free survival rates in those who progress on frontline treatments. Additionally, the company faces challenges with poor oral bioavailability of its drug, necessitating intramuscular injections that may limit dose administration and overall treatment efficacy.
This aggregate rating is based on analysts' research of Celcuity and is not a guaranteed prediction by Public.com or investment advice.
Celcuity (CELC) Analyst Forecast & Price Prediction
Start investing in Celcuity (CELC)
Order type
Buy in
Order amount
Est. shares
0 shares